Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.
1. A vector comprising a nucleic acid encoding Cas9 operably linked to at least one nuclear localization signal (NLS), wherein the nucleic acid is under the control of a promoter which is inducible in a eukaryotic cell or a control element which allows for conditional expression of the Cas9 in a eukaryotic cell, and wherein the Cas9 is a Cre recombinase dependent Cas9.
2. The vector of claim 1 , wherein the vector comprises a nucleic acid encoding a stop cassette element, wherein the stop cassette element is loxP-SV40 polyA x3-loxP.
3. The vector of claim 2 , wherein the nucleic acid encoding the stop element is between the promoter and the nucleic acid encoding Cas9.
4. A eukaryotic cell comprising the vector of claim 2 .
5. The vector of claim 1 , wherein the Cas9 is a Streptococcus pyogenes Cas9.
6. The vector of claim 1 , further comprising a nucleic acid encoding a peptide cleavage sequence.
7. The vector of claim 1 , further comprising a nucleic acid encoding a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE).
8. The vector of claim 1 , further comprising a nucleic acid encoding a bovine growth hormone poly-A signal sequence (bGHpolyA).
9. The vector of claim 1 , further comprising a nucleic acid encoding a peptide cleavage sequence, a WPRE and a bGHpolyA.
10. A eukaryotic cell comprising the vector of claim 1 .
11. The eukaryotic cell of claim 10 , wherein the cell is a mouse cell.
12. The vector of claim 1 , wherein the vector further comprises nucleic acid(s) to target insertion of the nucleic acid encoding the Cas9 and the at least one NLS, and the promoter or the control element, to a Rosa26 locus.
13. The vector of claim 1 , wherein the at least one NLS is selected from the group consisting of: PKKKRKV (SEQ ID NO:62), KRPAATKKAGQAKKKK (SEQ ID NO:63), PAAKRVKLD (SEQ ID NO:64), RQRRNELKRSP (SEQ ID NO:65), NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO:66), RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO:67), VSRKRPRP (SEQ ID NO:68), PPKKARED (SEQ ID NO:69), PQPKKKPL (SEQ ID NO:70), SALIKKKKKMAP (SEQ ID NO:71), DRLRR (SEQ ID NO:72), PKQKKRK (SEQ ID NO:73), RKLKKKIKKL (SEQ ID NO:74), REKKKFLKRR (SEQ ID NO:75), KRKGDEVDGVDEVAKKKSKK (SEQ ID NO:76), and RKCLQAGMNLEARKTKK (SEQ ID NO:77).
14. A vector comprising a nucleic acid encoding Cas9 operably liked to a first NLS at the amino-terminus (N-terminus) of the Cas9 and a second NLS at the carboxy-terminus (C-terminus) of the Cas9, wherein the nucleic acid is under the control of a promoter which is inducible in a eukaryotic cell or a control element which allows for conditional expression of the Cas9 in a eukaryotic cell.
15. A vector comprising a nucleic acid encoding Cas9 operably linked to a first NLS near the N-terminus of the Cas9 and a second NLS near the C-terminus of the Cas9, wherein the nucleic acid is under the control of a promoter which is inducible in a eukaryotic cell or a control element which allows for conditional expression of Cas9 in a eukaryotic cell, wherein the first NLS is considered near the N-terminus of the Cas9 when the nearest amino acid of the first NLS is within about 50 amino acids along the polypeptide chain from the N-terminus of the Cas9, and wherein the second NLS is considered near the C-terminus of the Cas9 when the nearest amino acid of the second NLS is within about 50 amino acids along the polypeptide chain from the C-terminus of the Cas9.